Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | WNT3 | P56703 | 1/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903617 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1TSHRMAPT | |
| SCHEMBL946514 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1TSHRMAPT | |
| SCHEMBL16584576 | 0.92 | FKBP1A (0.41) | MEN1KMT2AALDH1A1TSHRMAPT | |
| SCHEMBL15281912 | 0.92 | FKBP1A (0.41) | MEN1KMT2AALDH1A1TSHRMAPT | |
| SCHEMBL8266791 | 0.92 | FKBP1A (0.41) | MEN1KMT2AALDH1A1TSHRMAPT | |
| SCHEMBL3366889 | 0.87 | KLK7 (0.34) | MEN1KMT2AALDH1A1FKBP1ACHRM2 | |
| SCHEMBL16082361 | 0.87 | KLK7 (0.34) | MEN1KMT2AALDH1A1FKBP1ACHRM2 | |
| SCHEMBL1372911 | 0.87 | CHRM2 (0.41) | MAPTCHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL713924 | 0.87 | CHRM2 (0.41) | MAPTCHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL30289778 | 0.87 | CHRM2 (0.41) | MAPTCHRM2CHRM1CHRM3WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118150658-A | Intramolecular anchor chain electrochemical sensor based on tag protein and receptor protein and preparation and application thereof | 华东师范大学 | 2024-06-07 | — | — | CN | claimed |
| CN-115894338-B | Method for preparing Ritlecritinib intermediate by chemical-biological enzyme coupling | 华南理工大学 | 2024-02-13 | — | — | CN | claimed |
| CN-112877379-B | Method for synthesizing N- [ (3R, 6R) -6-methylpiperidine-3-yl ] tert-butyl carbamate by chemical enzyme method | 华南理工大学 | 2023-09-01 | — | — | CN | claimed |
| CN-115894338-A | Method for preparing Ritlecetinib intermediate by coupling chemical enzyme and biological enzyme | 华南理工大学 | 2023-04-04 | — | — | CN | claimed |
| CN-112877379-A | Method for synthesizing N- [ (3R,6R) -6-methylpiperidine-3-yl ] carbamic acid tert-butyl ester by chemoenzymatic method | 华南理工大学 | 2021-06-01 | — | — | CN | claimed |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | INCYTE CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090333-A1 | COMBINATION USING A KRAS G12D INHIBITOR AND CHEMOTHERAPY COMBINATIONS AS WELL AS THEIR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090323-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR AND ITS USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12600720-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2026-04-14 | — | — | US | disclosed |
| WO-2025264645-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250304601-A1 | Processes for Preparing KRAS Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| US-20070249678-A1 | SYNTHESIS AND USES OF PYROGLUTAMIC ACID DERIVATIVES | PRODIMED, S.A. (ES) | 2007-10-25 | — | — | US | disclosed |
| EP-1847536-A1 | Synthesis and uses of pyroglutamic acid derivatives | Prodimed, S.A. (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | MEN1 1218/4885KMT2A 3890/4885ALDH1A1 1502/4885 |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | MEN1 2716/4885KMT2A 4028/4885ALDH1A1 1700/4885 |
| US-20070249678-A1 | SYNTHESIS AND USES OF PYROGLUTAMIC ACID DERIVATIVES | GLUL, RIMKLA, PHKG1 | MEN1 869/4885KMT2A 579/4885ALDH1A1 3368/4885 |
| US-20250304601-A1 | Processes for Preparing KRAS Inhibitors | KRAS, NRAS, HRAS | MEN1 389/4885KMT2A 1561/4885ALDH1A1 3367/4885 |
| US-20260137674-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR | KRAS, NRAS, DCTD | MEN1 3490/4885KMT2A 2595/4885ALDH1A1 3637/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | MEN1 235/4885KMT2A 2733/4885ALDH1A1 785/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | MEN1 1618/4885KMT2A 3845/4885ALDH1A1 1369/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | MEN1 184/4885KMT2A 3271/4885ALDH1A1 869/4885 |
| US-12600720-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, MC2R | MEN1 4622/4885KMT2A 4075/4885ALDH1A1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.